Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 2

3(50.0%)

Phase 3

2(33.3%)

N/A

1(16.7%)

6Total

Phase 2(3)

Phase 3(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT05510895Phase 2Completed

Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer

Role: collaborator

NCT01848028Recruiting

PsoBest - The German Psoriasis Registry

Role: collaborator

NCT03507413Phase 2Active Not Recruiting

Metformin Therapy in Non-diabetic AAA Patients

Role: collaborator

NCT04727541Phase 2Terminated

Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer

Role: collaborator

NCT01297465Phase 3Completed

PERgoveriS In Stratified Treatment for Assisted Reproductive Technique

Role: collaborator

NCT04026282Not ApplicableUnknown

To Investigate the Cumulative Live Birth Rates Using GnRH Antagonist or Agonist Protocol for COS in ART Treatment

Role: collaborator

NCT01081639Phase 3Completed

To Evaluate the Convenience, Safety and Efficacy of Follitropin Alfa Liquid Pen Compared With Follitropin Beta Liquid Pen

Role: collaborator

NCT01075711Completed

Determine the Improvement in Activity Status/Quality of Life (QoL) of Patients With Rheumatoid Arthritis (RA) During Treatment With Lodotra (Prednisone)

Role: collaborator

All 8 trials loaded